BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Stock Information for BioLineRx Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioLineRx Ltd.

BioLineRx Reports 2025 Financial Results and Provides Corporate Update
BioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.